Core Viewpoint - A class action lawsuit has been filed against Fermi Inc. for violations of federal securities laws, particularly related to misleading statements made during its IPO period [1][2]. Group 1: Class Action Details - The class period for the lawsuit is defined as from Fermi's IPO in October 2025 to December 11, 2025 [2]. - The lawsuit claims that Fermi made false and misleading statements regarding its reliance on a single potential tenant for its "Project Matador" campus, which was at risk of terminating its funding commitment [2]. Group 2: Investor Participation - Shareholders who purchased shares during the class period are encouraged to contact the DJS Law Group for potential lead plaintiff appointments, although this is not required for recovery [1][3]. - The deadline for participation in the lawsuit is set for March 6, 2026 [2].

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. for alleged violations of the Securities Exchange Act, specifically for making false and misleading statements regarding its financial reporting [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from July 18, 2024, to November 12, 2025, with a deadline for lead plaintiff appointments set for March 9, 2026 [2]. - The complaint alleges that Ardent Health utilized a 180-day cliff on accounts receivable, allowing the company to report inflated amounts and delay loss recognition, rendering its public statements materially misleading [2]. Group 2: Investor Participation - Shareholders who purchased shares during the class period are encouraged to contact the law firm for potential lead plaintiff appointments, although such an appointment is not necessary to participate in any recovery [2][3].

VAT Group AG (19V.F,VACN.SW) reported preliminary fourth-quarter sales of 257 million Swiss francs, ahead of the guidance range of 225 to 245 million francs. Fourth-quarter sales declined 9% year on year. Adjusted for the sales shifted from the third-quarter 2024 to the fourth-quarter 2024, sales would have been down 1%. The company recorded preliminary fourth-quarter orders of around 305 million francs, up 14% year on year. The company said its detailed results and an update on the outlook for 2026 will b ...

Core Insights - The world's largest contract chip maker achieved record earnings in Q4 2025 despite facing supply challenges and pressure from the U.S. government to relocate semiconductor production to the United States [1] Company Performance - The company reported another quarter of record earnings, indicating strong financial performance amidst ongoing supply chain issues [1] - The earnings growth reflects the company's ability to navigate market challenges effectively [1] Industry Context - The semiconductor industry is experiencing significant pressure from U.S. policies aimed at increasing domestic production [1] - Supply challenges continue to impact the industry, yet the leading contract chip maker has managed to maintain its competitive edge [1]

Oracle was sued on Wednesday by bondholders who say they suffered losses because the company chaired by billionaire Larry Ellison concealed its need to sell significant additional debt to build out its artificial intelligence infrastructure.The proposed class action was filed in a New York state court in Manhattan on behalf of investors who said they bought $18 billion of senior notes and bonds that Oracle issued on September 25, shortly after the software and cloud computing company signed a $300 billion, ...

Core Viewpoint - The European Central Bank (ECB) needs to be vigilant due to the U.S. administration's criticism of the Federal Reserve, which introduces new risks to the economic outlook [1] Group 1 - ECB policymaker Martins Kazaks highlighted the potential impact of U.S. political actions on global economic stability [1]

After several quiet years, Singapore’s initial public offering (IPO) market finally showed signs of life in 2025. The Lion City led Southeast Asia’s (SEA) IPO market with US$1.6 billion raised in the first 10.5 months of the year, driven by two major REITs.1Government initiatives, stronger liquidity, and improved investor appetite contributed to this revival.What’s in store for 2026? We may get some clues from 2025’s IPO debuts.Centurion Accommodation REIT (SGX: 8C8U)Centurion Accommodation REIT (SGX: 8C8U) ...

Warren Buffett made $97 million the last time he bought this misunderstood asset.Legendary investor Warren Buffett stepped down as chairman and CEO of Berkshire Hathaway (BRK.A +0.15%) (BRK.B 0.42%) as of Jan. 1, as planned. And with 13-F filings for the fourth quarter of 2025 due on Feb. 14, 45 days after the end of the calendar quarter, I predict they will reveal that Buffett bought vast quantities of silver in the last days of his tenure.Of course, this is speculation, and only on Feb. 14 will we know fo ...

Core Insights - Sanofi has received approval from the National Medical Products Administration in China for two innovative medicines: Myqorzo (aficamten) for obstructive hypertrophic cardiomyopathy (oHCM) and Redemplo (plozasiran) for familial chylomicronaemia syndrome (FCS) [1][2][9] Myqorzo (aficamten) - Myqorzo is a selective, small-molecule cardiac myosin inhibitor designed to improve functional capacity and relieve symptoms in patients with oHCM, the most common monogenic inherited cardiovascular disorder [2][7] - The approval was based on the positive results from the pivotal SEQUOIA-HCM phase 3 study (clinical study identifier: NCT05186818) [2] - Myqorzo has been designated as breakthrough therapy and orphan drug in the US, and breakthrough therapy in China, with a positive opinion for marketing authorization in the EU expected in Q1 2026 [8] Redemplo (plozasiran) - Redemplo is a small-interfering RNA (siRNA) medicine that suppresses the production of apoC-III, targeting triglyceride reduction in patients with FCS, a severe and rare disease characterized by extremely high triglyceride levels [3][11] - The approval was based on the positive results from the pivotal PALISADE phase 3 study (clinical study identifier: NCT05089084) [3] - Redemplo has received multiple designations including breakthrough therapy and orphan drug in the US, and is also approved in Canada and China for treating FCS patients [11][12] Hypertrophic Cardiomyopathy (HCM) - HCM is characterized by abnormal thickening of the heart muscle, leading to impaired heart function and various symptoms such as chest pain and shortness of breath [4][5] - It has two forms: obstructive HCM (oHCM) affecting two-thirds of patients and non-obstructive HCM affecting one-third [5] - Serious complications from HCM include atrial fibrillation, stroke, and it is a leading cause of sudden cardiac death in young people [6] Familial Chylomicronaemia Syndrome (FCS) - FCS is a rare disease leading to triglyceride levels exceeding 880 mg/dL (9.94 mmol/L), which can result in severe complications such as pancreatitis and diabetes [10] - The approval of Redemplo addresses a significant unmet medical need for patients suffering from this condition [3][11] Sanofi's Commitment - The approvals of Myqorzo and Redemplo highlight Sanofi's long-term commitment to providing innovative medicines to patients in China, particularly in areas with large unmet medical needs [2][9]

Core Viewpoint - Trip.com Group Limited (TCOM) is under investigation by China's State Administration for Market Regulation for potential monopolistic behavior, which has led to a significant drop in its stock price by 17% on January 14, 2026 [1][2]. Group 1: Company Investigation - Wohl & Fruchter LLP is investigating whether TCOM has violated federal securities laws in light of the ongoing investigation by Chinese authorities [1]. - The investigation pertains to potential violations of the Anti-Monopoly Law of the People's Republic of China [1]. Group 2: Stock Market Reaction - Following the announcement of the investigation, TCOM's stock price experienced a decline of 17% during trading on January 14, 2026 [2].